Jeonjinbio

At a glance

Jeonjinbio filed 25 disclosures in the last 12 months, including 5 insider and 5 5% holder. The most recent key filing was on Aug 21.

Revenue for 2025 was ₩13.7B, down 28.9% on 2024. It made an operating loss of ₩342.9M. Debt was 6% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩5.8B and operating loss of ₩460.3M.

The 2025 annual report lists 57 employees with an average tenure of 3.4 years and average pay of ₩27.2M, #1822 of 1,829 listed companies by average pay. Its 9 directors and auditors were paid ₩114.9M each on average. It paid no cash dividend for 2025. 이태훈 and related parties held 6.84% at year end.

From the 2025 annual report

Staff: 57 (31 men, 26 women), of whom 27 on fixed-term contracts. Total pay for the year: ₩1.5B. Directors and auditors: 9, paid ₩1B in total.

No cash dividend was paid for 2025.

Largest shareholder

이태훈 holds 3.48%; with 1 related party the group holds 6.84% of common shares at year end.

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary